ITM Isotope Technologies Munich

ITM Isotope Technologies Munich is focused on developing and commercializing diagnostic and therapeutic radionuclides and radiopharmaceuticals.In May 2019, a new production site to increase the production capacity of no-carrier-added (n.c.a.) Lutetium-177 and high-purity (n.c.a.) Lutetium-177 containing radiopharmaceuticals was established in Neufahrn, Munich.In August 2022, the company announced that it signed an agreement to acquire Positron Precision.In June 2023, ITM Isotope Technologies announced an equity investment round of €255 million.In February 2022, the company and Grand Pharmaceutical Group had entered into a definitive agreement under which Grand Pharmaceutical would make a EUR 25 million (USD 28 million) equity investment in the company.In March 2016, the company raised EUR 20 million in equity from Medtech Focused Family Office